trending Market Intelligence /marketintelligence/en/news-insights/trending/9VH48f3-dSo35yOjtkLscQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Durect stock falls after psoriasis drug fails in mid-stage study

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Durect stock falls after psoriasis drug fails in mid-stage study

Durect Corp.'s DUR-928 failed to show that it was better than a placebo in treating patients with mild to moderate plaque psoriasis in a mid-stage study.

The Cupertino, Calif.-based biopharmaceutical company's stock was down 30.79% to $2.63 as of 11:07 a.m. ET on Jan. 2 on Nasdaq.

Under the phase 2a trial, DUR-928 was evaluated in 22 patients with mild to moderate plaque psoriasis, a condition wherein the skin gets red, itchy, scaly and patchy.

For 28 days, DUR-928 was applied topically once daily on one arm of the patients while a placebo was applied on the arm, targeting similar patches.

Durect in a Jan. 2 press release said DUR-928 failed to meet the primary endpoint of improving skin clarity as well as the secondary goals. DUR-928 was safe and well-tolerated in the trial.

On the basis of the study results, Durect will stop the clinical development of DUR-928 to treat plaque psoriasis, President and CEO James Brown stated. "With the recently announced positive results from our Phase 2a alcoholic hepatitis trial, our focus moving forward with DUR-928, will be on completing the NASH trial in the first half of this year and initiating the Phase 2b AH trial in the middle of the year."

Previously, DUR-928 helped reduce the severity of symptoms in patients with alcoholic hepatitis, a liver disease, in a mid-stage study.